Current Challenges and Opportunities in Cost Effective and Affordable Biosimilars

27th October 2014

Category: Biosimilars

Tags: ,

By: Dr Daniel Galbraith, CSO,

Biosimilars challenge us in many ways but for me these issues can be divided into those for a scientist, those for the industry and those for the patient. In my job, as a CSO working in Contract Research Organization, I have found Biosimilars have forced us to better understand the biological aspects of these drugs. More

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy